Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma

被引：0
|
作者：
Yujing Xin
Xinyuan Zhang
Ning Liu
Gang Peng
Xiaoyu Huang
Xiaojing Cao
Xiang Zhou
Xiao Li
机构：
[1] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital
[2] Shandong University,School of Software
来源：
Hepatology International | 2023年 / 17卷
关键词：
Lenvatinib; PD-1 inhibitor; Transarterial chemoembolization; Hepatocellular carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：753 / 764
页数：11
相关论文
共 50 条
  • [11] Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
    Cai, Mingyue
    Huang, Wensou
    Huang, Jingjun
    Shi, Wenbo
    Guo, Yongjian
    Liang, Licong
    Zhou, Jingwen
    Lin, Liteng
    Cao, Bihui
    Chen, Ye
    Zhou, Juan
    Zhu, Kangshun
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [12] Hepatocellular Carcinoma with Radiological Progression: Lenvatinib Plus PD-1 Inhibitor Combined with Microwave Ablation and Synchronous Transarterial Chemoembolization
    Shi, Qin
    Huang, Peng
    Zhang, Zihan
    Zhang, Wen
    Liu, Lingxiao
    Yan, Zhiping
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 1861 - 1871
  • [13] Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
    Sun, Liwei
    Xu, Xuelong
    Meng, Fanguang
    Liu, Qian
    Wang, Hankang
    Li, Xiaodong
    Li, Guijie
    Chen, Feng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [14] Effectiveness of transarterial chemoembolization combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma
    Cao, Fei
    Yang, Yi
    Si, Tongguo
    Luo, Jun
    Zeng, Hui
    Zhang, Zhewei
    Chen, Yi
    Zheng, Jiaping
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [15] Present and prospect of transarterial chemoembolization combined with tyrosine kinase inhibitor and PD-1 inhibitor for unresectable hepatocellular carcinoma
    Zhang, Rui
    Liu, Yan-Hui
    Li, Yu
    Li, Nan-Nan
    Li, Zheng
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (11)
  • [16] Effectiveness and safety of transarterial chemoembolization combined with PD-1 inhibitors and lenvatinib for unresectable intrahepatic cholangiocarcinoma
    Huang, Jin-Tao
    Hu, Di
    Hong, Xin
    Zhou, Wen-Jie
    Shen, Jian
    Lv, Peng-Hua
    Zhu, Xiao-Li
    EUROPEAN RADIOLOGY EXPERIMENTAL, 2025, 9 (01)
  • [17] Efficiency and Stability of Transarterial Chemoembolization Combined With or Without Lenvatinib for Unresectable Hepatocellular Carcinoma
    Zong, Zheng
    Tang, Rongyu
    Li, Mingyu
    Xiong, Xinmiao
    Li, Daixin
    Fan, Jing
    Ye, Wei
    Xue, Chenqi
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2024, 35 (03): : 212 - 222
  • [18] Efficacy of Lenvatinib Combined with PD-1 Inhibitor versus Sorafenib and PD-1 Inhibitor with or Without TACE for Hepatocellular Carcinoma with
    Duan, Wen-Bin
    Wang, Xiao-Hui
    Zhang, Guo-Can
    He, Zhuo
    Li, Shao-Qiang
    Zhou, Jie
    IMMUNOTARGETS AND THERAPY, 2024, 13 : 247 - 258
  • [19] Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
    Jiang, Jiayun
    Zhang, Hui
    Lai, Jiejuan
    Zhang, Shiyu
    Ou, Yanjiao
    Fu, Yu
    Zhang, Leida
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1607 - 1622
  • [20] Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
    Pan, Hongyu
    Ruan, Minghao
    Jin, Riming
    Zhang, Jin
    Li, Yao
    Wu, Dong
    Sun, Wen
    Wang, Ruoyu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345